ArticleInternational urology and nephrology2025
Assessment of quality of life in patients undergoing hyperthermic intravesical chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24).
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient-Reported Outcome Instruments in Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review.Oncology and therapy · 2026Pooled it
- Hyperthermic Intravesical Chemotherapy as a Bladder-Sparing Alternative to BCG in the Management of Non-Muscle-Invasive Bladder Cancer: A Systematic Review of Oncological Outcomes in the Era of BCG Shortage.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to assess changes in quality of life (QoL) experienced by patients undergoing hyperthermic intravesical chemotherapy (HIVEC), using validated EORTC QLQ-C30 and EORTC QLQ-NMIBC24 questionnaires.
methodsBetween 2021 and 2024, 67 patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who experienced BCG failure or intolerance were enrolled in an HIVEC regimen at our institution. Functional outcomes were evaluated through the EORTC QLQ-C30 and EORTC QLQ-NMIBC24 questionnaires administered at baseline (prior to treatment), after six weekly instillations (induction phase), after three monthly instillations (3 months), and after an additional six monthly instillations (9 months). Each response was assigned a specific score to assess QoL variations over time.
resultsOf the 67 patients enrolled, 13 discontinued the therapy. After 9 months, 54 patients completed the EORTC QLQ-C30 and NMIBC24 questionnaires. The QLQ-C30 results indicate that the therapy did not significantly affect daily activities, despite reported increases in fatigue and weakness. However, negative impacts were observed in terms of pain, concentration, and engagement in recreational activities, alongside growing concerns about disease recurrence. The NMIBC24 questionnaire revealed an increase in urinary frequency, associated insomnia, and discomfort related to catheter use. Additionally, there was a decline in libido and anxiety about contaminating their partners.
conclusionsWhile the initial phase of HIVEC therapy significantly impacts QoL, particularly regarding pain and psychological concerns, it does not drastically affect daily activities in the long term. Nevertheless, the treatment has a negative influence on both physical and mental well-being, contributing to increased anxiety and limitations in social and recreational activities, as well as reduced sexual function.
Indexed as
Identifiers
39960577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.